comparemela.com

Latest Breaking News On - ஆல்பர்ட்டா நீரிழிவு நோய் நிறுவனம் - Page 1 : comparemela.com

Limiting the release of fat into the bloodstream during heart failure could help improve outcomes

Limiting the release of fat into the bloodstream during heart failure could help improve outcomes University of Alberta researchers have found that limiting the amount of fat the body releases into the bloodstream from fat cells during heart failure could help improve outcomes for patients. In a recent study published in the American Journal of Physiology, Jason Dyck, professor of pediatrics in the Faculty of Medicine & Dentistry and director of the U of A s Cardiovascular Research Centre, found that mice with heart failure that were treated with a drug blocking the release of fat into the bloodstream from fat cells saw less inflammation in the heart and throughout the body, and had better outcomes than a control group.

Fat cells may influence how the body reacts to heart failure, study shows

 E-Mail IMAGE: Pediatric cardiology researcher Jason Dyck and his team found that limiting the release of fat into the body from fat cells during heart failure led to better outcomes in mice and. view more  Credit: University of Alberta University of Alberta researchers have found that limiting the amount of fat the body releases into the bloodstream from fat cells during heart failure could help improve outcomes for patients. In a recent study published in the American Journal of Physiology, Jason Dyck, professor of pediatrics in the Faculty of Medicine & Dentistry and director of the U of A s Cardiovascular Research Centre, found that mice with heart failure that were treated with a drug blocking the release of fat into the bloodstream from fat cells saw less inflammation in the heart and throughout the body, and had better outcomes than a control group.

CIHR and JDRF funding drives efforts to find new stem cell-based therapies for Type 1 diabetes

Date Time Share CIHR and JDRF funding drives efforts to find new stem cell-based therapies for Type 1 diabetes University of Alberta researchers are among two Canadian research teams chosen for significant new funding from the Government of Canada and JDRF Canada to develop new stem cell-based therapies for treating Type 1 diabetes. The projects will each receive $1.5 million from the Canadian Institutes of Health Research Institute of Nutrition, Metabolism and Diabetes (CIHR-INMD) along with matching dollars from JDRF Canada, for total funding of $3 million per project over five years. The funding investment marks the anniversary of the Canadian discovery of insulin 100 years ago, a significant turning point in the work to defeat diabetes.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.